glp-1 drugs comparison New oral drug delivers up to 12% weight loss in 36 weeks 1 boosting + Weight Support + Digestive Support + Heart and Circulatory Support + Caffeine PDB-101: Molecule of the Month:

A recent study from British Columbia, Canada, explored the effects of GLP-1 receptor agonists in nearly 11,000 patients with both autoimmune conditions and diabetes

The aglycone of ginsenoside Rg3 enables glucagon-like peptide-1 secretion in enteroendocrine cells and alleviates hyperglycemia in type 2 diabetic mice

GLP-1 RAs did not improve the change in LVEF (mean difference [MD]): 0.86, p = 0.12, left-ventricular end-diastolic volume (LVEDV) (MD: 3.54, p = 0.11), left-ventricular end-systolic volume (LVESV) (MD: 2.78, p = 0.07) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) (MD: 140.36, p = 0.08)

Saxenda vs Ozempic: Comparing GLP-1 Weight Loss Medications Saxenda and Ozempic are both GLP-1 receptor agonists, meaning they work through the same fundamental mechanism

PF-06882961 agonist activity was assessed at both the cAMP and Arr pathways and compared to the marketed GLP-1R agonists exenatide and liraglutide

doi: 10.1161/CIRCULATIONAHA.117.028136